|Bid||0.1370 x 300400|
|Ask||0.1400 x 800|
|Day's range||0.1263 - 0.1529|
|52-week range||0.0950 - 1.9800|
|Beta (5Y monthly)||1.25|
|PE ratio (TTM)||N/A|
|Earnings date||10 Aug 2022 - 15 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.13|
CHICAGO, May 17, 2022--Exicure today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference.
CHICAGO, May 16, 2022--Exicure today reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.
CHICAGO, May 10, 2022--Exicure, Inc.® (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that it has agreed to sell an aggregate of 26,021,111 shares of its common stock at a purchase price of $0.1937 per share to certain accredited investors in a private placement in public equity ("PIPE") financing. The purch